These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 29249291)

  • 1. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
    Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
    Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.
    Gershman B; Moreira DM; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    Eur Urol; 2017 Aug; 72(2):300-306. PubMed ID: 28094055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
    Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
    Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience.
    Liu Z; Lv J; Ding K; Fu Q; Cao Q; Wang F
    Int J Urol; 2009 Mar; 16(3):268-73. PubMed ID: 19087209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
    Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
    Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
    Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
    World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
    Rini B; Goddard A; Knezevic D; Maddala T; Zhou M; Aydin H; Campbell S; Elson P; Koscielny S; Lopatin M; Svedman C; Martini JF; Williams JA; Verkarre V; Radulescu C; Neuzillet Y; Hemmerlé I; Timsit MO; Tsiatis AC; Bonham M; Lebret T; Mejean A; Escudier B
    Lancet Oncol; 2015 Jun; 16(6):676-85. PubMed ID: 25979595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
    Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
    Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
    Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.